Literature DB >> 29474644

DICER1 Mutations Are Frequent in Adolescent-Onset Papillary Thyroid Carcinoma.

Jonathan D Wasserman1,2, Nelly Sabbaghian3, Somayyeh Fahiminiya4, Rose Chami5, Ozgur Mete6, Meryl Acker1, Mona K Wu3,7, Adam Shlien5,8, Leanne de Kock3,7, William D Foulkes3,4,7.   

Abstract

Context: Papillary thyroid carcinoma (PTC) is a common malignancy in adolescence and is molecularly and clinically distinct from adult PTC. Mutations in the DICER1 gene are associated with thyroid abnormalities, including multinodular goiter and differentiated thyroid carcinoma. Objective: In this study, we sought to characterize the prevalence of DICER1 variants in pediatric PTC, specifically in tumors without conventional PTC oncogenic alterations. Patients: Patients (N = 40) who underwent partial or total thyroidectomy and who were <18 years of age at the time of surgery were selected. Design: The 40 consecutive thyroidectomy specimens (30 malignant, 10 benign) underwent genotyping for 17 PTC-associated variants, as well as full sequencing of the exons and exon-intron boundaries of DICER1.
Results: Conventional alterations were found in 12 of 30 (40%) PTCs (five BRAFV600E, three RET/PTC1, four RET/PTC3). Pathogenic DICER1 variants were identified in 3 of 30 (10%) PTCs and in 2 of 10 (20%) benign nodules, all of which lacked conventional alterations and did not recur during follow-up. DICER1 alterations thus constituted 3 of 18 (16.7%) PTCs without conventional alterations. The three DICER1-mutated carcinomas each had two somatic DICER1 alterations, whereas two follicular-nodular lesions arose in those with germline DICER1 mutations and harbored characteristic second somatic RNase IIIb "hotspot" mutations. Conclusions: DICER1 is a driver of pediatric thyroid nodules, and DICER1-mutated PTC may represent a distinct class of low-risk malignancies. Given the prevalence of variants in children, we advocate for inclusion of DICER1 sequencing and gene dosage determination in molecular analysis of pediatric thyroid specimens.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29474644     DOI: 10.1210/jc.2017-02698

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  20 in total

Review 1.  Proceedings of the North American Society of Head and Neck Pathology, Los Angeles, CA, March 20, 2022: DICER1-Related Thyroid Tumors.

Authors:  Madeline Sauer; Justine A Barletta
Journal:  Head Neck Pathol       Date:  2022-03-21

Review 2.  Overview of the 2022 WHO Classification of Familial Endocrine Tumor Syndromes.

Authors:  Vania Nosé; Anthony Gill; José Manuel Cameselle Teijeiro; Aurel Perren; Lori Erickson
Journal:  Endocr Pathol       Date:  2022-03-13       Impact factor: 3.943

3.  Expanding the spectrum of thyroid carcinoma with somatic DICER1 mutation: a survey of 829 thyroid carcinomas using MSK-IMPACT next-generation sequencing platform.

Authors:  Charles A Ghossein; Snjezana Dogan; Nada Farhat; Iñigo Landa; Bin Xu
Journal:  Virchows Arch       Date:  2021-09-27       Impact factor: 4.064

4.  Analyzing the Role of DICER1 Germline Variations in Papillary Thyroid Carcinoma.

Authors:  Sule Canberk; Joana C Ferreira; Luísa Pereira; Rui Batısta; Andre F Vieira; Paula Soares; Manuel Sobrinho Simões; Valdemar Máximo
Journal:  Eur Thyroid J       Date:  2020-08-06

5.  Poorly differentiated thyroid carcinoma of childhood and adolescence: a distinct entity characterized by DICER1 mutations.

Authors:  Rebecca D Chernock; Barbara Rivera; Nicla Borrelli; D Ashley Hill; Somayyeh Fahiminiya; Tasha Shah; Anne-Sophie Chong; Barina Aqil; Mitra Mehrad; Thomas J Giordano; Rachel Sheridan; Meilan M Rutter; Louis P Dehner; William D Foulkes; Yuri E Nikiforov
Journal:  Mod Pathol       Date:  2020-01-14       Impact factor: 7.842

6.  The prevalence of germline DICER1 pathogenic variation in cancer populations.

Authors:  Jung Kim; Kris Ann P Schultz; Dana Ashley Hill; Douglas R Stewart
Journal:  Mol Genet Genomic Med       Date:  2019-01-22       Impact factor: 2.183

7.  NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake.

Authors:  Young Ah Lee; Hyunjung Lee; Sun-Wha Im; Young Shin Song; Do-Youn Oh; Hyoung Jin Kang; Jae-Kyung Won; Kyeong Cheon Jung; Dohee Kwon; Eun-Jae Chung; J Hun Hah; Jin Chul Paeng; Ji-Hoon Kim; Jaeyong Choi; Ok-Hee Kim; Ji Min Oh; Byeong-Cheol Ahn; Lori J Wirth; Choong Ho Shin; Jong-Il Kim; Young Joo Park
Journal:  J Clin Invest       Date:  2021-09-15       Impact factor: 14.808

Review 8.  Macrofollicular Variant of Follicular Thyroid Carcinoma (MV-FTC) with a Somatic DICER1 Gene Mutation: Case Report and Review of the Literature.

Authors:  L Samuel Hellgren; Martin Hysek; Kenbugul Jatta; Jan Zedenius; C Christofer Juhlin
Journal:  Head Neck Pathol       Date:  2020-07-25

9.  High Prevalence of DICER1 Mutations and Low Frequency of Gene Fusions in Pediatric Follicular-Patterned Tumors of the Thyroid.

Authors:  Ja-Seong Bae; Seung-Hyun Jung; Mitsuyoshi Hirokawa; Andrey Bychkov; Akira Miyauchi; Sohee Lee; Yeun-Jun Chung; Chan Kwon Jung
Journal:  Endocr Pathol       Date:  2021-07-27       Impact factor: 3.943

Review 10.  DICER1 Syndrome: DICER1 Mutations in Rare Cancers.

Authors:  Jake C Robertson; Cheryl L Jorcyk; Julia Thom Oxford
Journal:  Cancers (Basel)       Date:  2018-05-15       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.